- Home
- XBIO
as of 08-25-2026 10:43am EST
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 6.9M | IPO Year: | 2011 |
| Target Price: | N/A | AVG Volume (30 days): | 35.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.60 | EPS Growth: | 38.52 |
| 52 Week Low/High: | $1.90 - $13.93 | Next Earning Date: | 05-13-2026 |
| Revenue: | $2,976,411 | Revenue Growth: | 19.04% |
| Revenue Growth (this year): | 2.81% | Revenue Growth (next year): | -16.67% |
| P/E Ratio: | -6.35 | Index: | N/A |
| Free Cash Flow: | -2286651.0 | FCF Growth: | N/A |
AI-Powered XBIO Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2026 Q2 Q2 2026 Earnings
8-K BUY Aug 7, 2026 · 100% conf.
Q2 2026 Earnings
8-K BUYAug 7, 2026 · 100% conf.
1D
+4.24%
$3.34
Act: -3.44%
5D
+11.13%
$3.56
Act: +2.50%
20D
+11.29%
$3.56
Transcript text not available. View on SEC.gov →
2026 Q1 Q1 2026 Earnings
8-K May 13, 2026
Q1 2026 Earnings
8-KMay 13, 2026
2025 Q4 Q4 2025 Earnings
8-K Mar 13, 2026
Q4 2025 Earnings
8-KMar 13, 2026
Compare XBIO vs Leading Stocks
See how XBIO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "XBIO Xenetic Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.